Compositions and methods for identifying and targeting...

Details Compositions and methods for identifying and targeting... Compositions and methods for identifying and targeting...

2004-06-14

2010-12-21

Goddard, Laura B (Department: 1642)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

Conjugated via claimed linking group, bond, chelating agent,...

C424S183100

Reexamination Certificate

active

07854933

ABSTRACT:
Screening and diagnostic reagents, kits and methods for primary and/or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing primary and/or metastatic stomach or esophageal cancer are disclosed.

REFERENCES:
patent: 4022878 (1977-05-01), Gross
patent: 4329281 (1982-05-01), Christenson et al.
patent: 4341763 (1982-07-01), Zygraich
patent: 4526716 (1985-07-01), Stevens
patent: 4584268 (1986-04-01), Ceriani et al.
patent: 4601896 (1986-07-01), Nugent
patent: 4659666 (1987-04-01), May et al.
patent: 4683195 (1987-07-01), Mullis
patent: 4683202 (1987-07-01), Mullis et al.
patent: 4729893 (1988-03-01), Letcher et al.
patent: 4736866 (1988-04-01), Leder et al.
patent: 4849227 (1989-07-01), Cho
patent: 4867973 (1989-09-01), Goers et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 4945050 (1990-07-01), Sanford et al.
patent: 4963263 (1990-10-01), Kauvar
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5000935 (1991-03-01), Faulk
patent: 5017487 (1991-05-01), Stunnenberg et al.
patent: 5037645 (1991-08-01), Strahilevitz
patent: 5075216 (1991-12-01), Innis et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5112606 (1992-05-01), Shiosaka et al.
patent: 5133866 (1992-07-01), Kauvar
patent: 5143854 (1992-09-01), Pirrung et al.
patent: 5160723 (1992-11-01), Welt et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5217869 (1993-06-01), Kauvar
patent: 5221736 (1993-06-01), Coolidge et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5237051 (1993-08-01), Garbers et al.
patent: 5252743 (1993-10-01), Barrett et al.
patent: 5270170 (1993-12-01), Schatz et al.
patent: 5271961 (1993-12-01), Mathiowitz et al.
patent: 5288514 (1994-02-01), Ellman
patent: 5324483 (1994-06-01), Cody et al.
patent: 5330892 (1994-07-01), Vogelstein et al.
patent: 5338665 (1994-08-01), Schatz et al.
patent: 5340474 (1994-08-01), Kauvar
patent: 5350741 (1994-09-01), Takada
patent: 5352775 (1994-10-01), Albertsen et al.
patent: 5366862 (1994-11-01), Venton et al.
patent: 5384261 (1995-01-01), Winkler et al.
patent: 5395750 (1995-03-01), Dillon et al.
patent: 5399347 (1995-03-01), Trentham et al.
patent: 5405783 (1995-04-01), Pirrung et al.
patent: 5412087 (1995-05-01), McGall et al.
patent: 5420328 (1995-05-01), Campbell
patent: 5424186 (1995-06-01), Fodor et al.
patent: 5430138 (1995-07-01), Urdea et al.
patent: 5437977 (1995-08-01), Segev
patent: 5443816 (1995-08-01), Zamora et al.
patent: 5518888 (1996-05-01), Waldman
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5593825 (1997-01-01), Carmen et al.
patent: 5601990 (1997-02-01), Waldman
patent: 5731159 (1998-03-01), Waldman
patent: 5879656 (1999-03-01), Waldman
patent: 5957909 (1999-09-01), Hammons et al.
patent: 5962220 (1999-10-01), Waldman
patent: 6060037 (2000-05-01), Waldman
patent: 6130043 (2000-10-01), Billing-Medel et al.
patent: 2004/0258687 (2004-12-01), Waldman et al.
patent: 2005/0287067 (2005-12-01), Wolfe et al.
patent: 0 846 949 (1998-06-01), None
patent: 01 92 2738 (2003-02-01), None
patent: PCT/US90/01515 (1990-10-01), None
patent: WO 92/14470 (1992-09-01), None
patent: PCT/US94/12232 (1995-05-01), None
patent: WO 97/42220 (1997-11-01), None
patent: WO 97/42506 (1997-11-01), None
patent: WO 98/41864 (1998-09-01), None
patent: WO 99/07726 (1999-02-01), None
patent: WO 00/20640 (2000-04-01), None
patent: WO 01/73132 (2001-06-01), None
patent: 839512 (1998-12-01), None
Debuyne et al, Expert Opinion Pharmacotherap., 2003, 4:1083-1096.
Park et al (Cancer Epidemiology, Biomarkers & Prevention, 2002, 11:739-744).
White et al. (2001, Ann. Rev. Med., 2001, 52:125-145).
Topp et al (Journal of Controlled Release, 1998, 53:15-23).
In re Alonso, Oct. 2008, US Court of Appeals for the Federal Circuit (p. 1-11 + cover).
Behrends et al., “The beta2 subunit of soluble guanylyl cyclase contains a human-specific frameshift and is expressed in gastric carcinoma,”Biochemical And Biophysical Research Communications(2000) 271(1):64-69.
Waldman et al., “Use of guanylyl cyclase c for detecting micrometastases in lymph nodes of patients with colon cancer,”Diseases of the Colon and Rectum(1998) 41:310-315.
European Search Report Dated Nov. 25, 2004 for European Application No. EP 01 92 2739.
Birbe et al., “Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract,” Human Pathology (2005) 36(2):170-179.
Fava et al., “Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood,” Journal of Clinical Oncology (2001) 19(19):3951-3959.
U.S. Appl. No. 08/468,449, filed Jun. 6, 1995, Waldman.
Almenoff et al.,“Ligand-based histochemical localization and capture of cells expressing heat-stable enterotoxin receptors”,Molecular Microbiology8:865-873 (1993).
Aimoto et al., “Chemical synthesis of a highly potent and heat-stable analog of an enterotoxin produced by a human strain of enterotoxigenicEscherichia coli”, Biochem. &Biophy. Res. Comm.. 112(1):320-326 (1983).
Aitken et al., “Recombinant enterotoxins as vaccines againstEscherichia coli-mediated diarrhea”,Vaccine11(2):227-233 (1993).
Alexander et al., “Oncogene Alterations in Rat Colon tumors Induced by -methyl-N-nitrosourea”,Am. J. Med. Sci. 303(1): 16-24 (1992).
Barchel et al.,Radioimaging and Radiotherapy, New York (1983).
Beck-Sickinger et al., “Neuropeptide Y: identification of the binding site”,Int. J. Peptide Protein Res. 36:522-530 (1990).
Berd et al., “Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine proceeded by cyclophsphamide”,Cancer Research46:2572-2577 (1986).
Berd et al., “Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases”,Cancer Research51:2731-2734 (1991).
Bjorn et al., “Antibody-pseudomonas exotoxin A conjugates cytotoxic to human breast cancer cells in vitro”,Cancer Research46:3262-3267 (1986).
Bjorn et al., “Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins”,Cancer Research45:1214-1221 (1985).
Blond-Elguindi et al., “Affinity Panning of a library of Peptides Displayed on Bacterophages Reveals the Binding Specificity of BiP”,Cell(1993).
Bodansky et al.,Peptide Synthesis, John Wiley and Sons, 2ndEd. (1976).
Bold et al., “Experimental Gene Therapy of Human Colon Cancer”,Surgery, 116(2): 189-196 (1994).
Bostick, P.J., “Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients”,J. Clinical Oncology16(8):2632-2640 (1998).
Bremer et al., “Safety and Efficacy of Radiopharmaceuticals”, Kristensen, K. (eds), Martinus Nijhoff Publishers, Dordrecht, The Netherlands, pp. 43-50 (1987).
Burgess et al., “Biological evaluation of a methonal-soluble, heat-stableEscherichia colienterotoxin in infant mice, pigs, rabbits, and calves”,Infection and Immunity21:526-531 (1978).
Bustin et al., “Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients”,British J. Cancer79(11/12):1813-1820 (1999).
Cagir et al., “Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer”,Am. Soc. Internal Med. 131(11):805-812 (1999).
Carepick et al., “TheEscherichia coliheat-stable enterotoxin is a long-lived superagonist of guanylin”,Infection&Immunity61(11):4710-4715 (1993).
Carrithers et al., “Escherichia coliHeat-Stable Toxin Receptors in Human Colonic Tumors”Gastroenterology107:1653-1661 (1994).
Carrithers et al., “Guanylyl cyclase C is a selective marker for metastatic colore

Affiliated with

Also associated with

Rating

Compositions and methods for identifying and targeting... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for identifying and targeting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for identifying and targeting... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4174724